Stand Up To Cancer — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Stand Up To Cancer appears in 17 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials17

Recruiting shown3

Roles1

SourceClinicalTrials.gov

Clinical trials

17 shown

Health Education Approach to Lung ScreeningNCT06070870 · collaborator · 2023-10-10

RECRUITING

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)NCT04434040 · collaborator · 2020-07-02

RECRUITING

Immunobiology Blood and Tissue Collection of Upper Aerodigestive MalignanciesNCT05995821 · collaborator · 2016-08-25

RECRUITING

Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC PatientsNCT05812274 · collaborator · 2023-05-31

TERMINATED

PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC)NCT04524195 · collaborator · 2021-02-01

TERMINATED

Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of Tomivosertib Combined With Paclitaxel in Advanced Breast CancerNCT04261218 · collaborator · 2020-08-25

COMPLETED

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate CancerNCT04262154 · collaborator · 2020-03-03

ACTIVE_NOT_RECRUITING

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast CancerNCT03568422 · collaborator · 2019-02-05

ACTIVE_NOT_RECRUITING

The Addition of Metformin to Definitive Radiotherapy in Patients With Stage III NSCLCNCT04170959 · collaborator · 2018-07-30

TERMINATED

Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast CancerNCT03566485 · collaborator · 2018-07-10

TERMINATED

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate CancerNCT02881242 · collaborator · 2018-01-30

ACTIVE_NOT_RECRUITING

Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung CancerNCT03215810 · collaborator · 2017-10-11

COMPLETED

Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.NCT03220477 · collaborator · 2017-08-04

ACTIVE_NOT_RECRUITING

High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor MalignanciesNCT03146962 · collaborator · 2017-03-29

COMPLETED

T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate CancerNCT02113657 · collaborator · 2014-08-20

COMPLETED

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.NCT01928576 · collaborator · 2013-11-06

COMPLETED

A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast CancerNCT01629615 · collaborator · 2012-06-01

COMPLETED

Drugs studied in this sponsor's trials

16 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Stand Up To Cancer as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

atezolizumab3

nivolumab2

paclitaxel2

abiraterone1

ascorbic acid1

azacitidine1

cobimetinib1

cyclophosphamide1

Sponsor roles

collaborator17

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.